Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 12 of 14, showing 10 Applications out of 131 total, starting on record 111, ending on 120

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

111.

ECCT/23/05/01   A5356
    A Phase II, Prospective, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety/Tolerability of Two Linezolid Dosing Strategies in Combination with a Short Course Regimen for the Treatment of Drug-Resistant Pulmonary Tuberculosis   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
MOI UNIVERSITY CLINICAL RESEARCH CENTRE
 
06-03-2024 View

112.

ECCT/24/02/03   MPZ-MAL-01
    A Phase 2a, Multicenter, Open-label, Dose-finding, Dose Escalation Study of Meplazumab in Adult Patients Diagnosed with   Uncomplicated Plasmodium falciparum Malaria       
Principal Investigator(s)
1. Videlis Nduba
Site(s) in Kenya
1. Kenya Medical Research Institute(KEMRI):Siaya Clinical Research Annex (Siaya county)
2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
3. AHERO CLINICAL TRIALS UNIT (Kisumu county)
 
08-03-2024 View

113.

ECCT/23/12/04   GBT021601 OLE
    An Open-label Extension Study to Evaluate the Long-term Safety of GBT021601 Administered to Participants with Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial       
Principal Investigator(s)
1. Jessie Nyokabi Githanga
2. Videlis Nduba
3. Bernhards Ragama Ogutu
Site(s) in Kenya
1. Gertude\'s Children\'s Hospital (Nairobi City county)
2. CENTER FOR RESEARCH IN THERAPEUTIC SCIENCES-STRATHMORE UNIVERSITY MEDICAL CENTER (CREATES (Nairobi City county)
3. KENYA MEDICAL RESEARCH INSTITUTE- CENTER FOR RESPIRATORY DISEASE RESEARCH(CRDR) (Nairobi City county)
4. KEMRI CRDR SIAYA (Siaya county)
 
17-03-2024 View

114.

ECCT/24/02/02   Sabin 003
    A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults   
Principal Investigator(s)
1. Prof. Videlis Nduba Nzioka
Site(s) in Kenya
KEMRI / CRDR, KEMRI Clinical Research Annex, Siaya County Referral Hospital Ground. P.O BOX 144-40600 ,Siaya, Kenya
 
23-04-2024 View

115.

ECCT/24/02/08   H06_02TP
    A Phase 2 single-blind, randomized, controlled, single center study to assess the immunogenicity and safety of a 2-dose schedule with GVGH altSonflex1-2-3 vaccine in African infants (H06_02TP)   
Principal Investigator(s)
1. Josphat Kosgei
Site(s) in Kenya
KEMRI WRP CRC KERICHO
 
31-05-2024 View

116.

ECCT/24/04/06   REACH 2
    Realizing Effectiveness Across Continents with Hydroxyurea (REACH):  A Phase I/II Prospective Trial of Hydroxyurea for Children and Young Adults with Sickle Cell Anaemia       
Principal Investigator(s)
1. Thomas Williams
2. Russell Ware
Site(s) in Kenya
Kilifi County Referal Hospital
 
28-06-2024 View

117.

ECCT/23/05/06   Sildenafil citrate to improve
    Sildenafil citrate to improve maternal and neonatal outcomes in low-resource settings:    a randomized feasibility trial   
Principal Investigator(s)
1. Nora Switchenko
Site(s) in Kenya
NAKURU COUNTY REFERRAL AND TEACHING HOSPITAL
 
05-07-2024 View

118.

ECCT/23/06/09   Hibiscus Kid\'s Study
    A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Walter Otieno
2. Videlis Nduba
Site(s) in Kenya
1. Kombewa Clinical research Centre (Kisumu county)
2. KEMRI, Siaya Clinical Research Annex (Kisumu county)
 
19-07-2024 View

119.

ECCT/24/04/03   SMAART-MAP trial
    Severe Malaria A Research and Trials consortium - Multisite Adaptive Platform trial   
Principal Investigator(s)
1. Prof Kathryn Maitland Maitland
Site(s) in Kenya
Kilifi County Hospital
 
29-08-2024 View

120.

ECCT/24/04/04   TNBC
    A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF TOBEMSTOMIG/RO7247669 COMBINED WITH NAB-PACLITAXEL COMPARED WITH   PEMBROLIZUMAB COMBINED WITH NABPACLITAXEL IN PARTICIPANTS WITH PREVIOUSLY UNTREATED, PD-L1-POSITIVE, LOCALLY-ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER   
Principal Investigator(s)
1. Mansoor Saleh
Site(s) in Kenya
1. University of Nairobi - Institute of Tropical and Infectious Diseases (Nairobi City county)
2. International Cancer Institute (Nandi county)
3. The Aga Khan University Hospital - Kenya (Nairobi City county)
 
19-09-2024 View